N-(6-aminopyridin-3-yl)benzamide | 936210-46-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-(6-aminopyridin-3-yl)benzamide
• CAS: 936210-46-7
• 化学式: C₁₂H₁₁N₃O
• mdl: MFCD17245545
• 分子量: 213.239
• InChiKey: JJTBRBXQRXNUNC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  68
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  N-(6-aminopyridin-3-yl)benzamide 、 1-chloro-5H-benzo[c][1,8]naphthyridin-6-one 在 palladium diacetate 、 sodium t-butanolate 、 2-二环己基磷-2,4,6-三异丙基联苯 作用下， 以 1,4-二氧六环 为溶剂， 生成 N-(6-(6-oxo-5,6-dihydrobenzo[c][1,8]naphthyridin-1-ylamino)pyridin-3-yl)benzamide
  参考文献：
  名称：

  SAR and evaluation of novel 5H-benzo[c][1,8]naphthyridin-6-one analogs as Aurora kinase inhibitors

  摘要：

  Several potent Aurora kinase inhibitors derived from 5H-benzo[c][1,8]naphthyridin-6-one scaffold were identified. A crystal structure of Aurora kinase A in complex with an initial hit revealed a binding mode of the inhibitor within the ATP binding site and provided insight for structure-guided compound optimization. Subsequent SAR campaign provided a potent and selective pan Aurora inhibitor, which demonstrated potent target modulation and antiproliferative effects in the pancreatic cell line, MIAPaCa-2. Furthermore, this compound inhibited phosphorylation of histone H3 (pHH3) in mouse bone morrow upon oral administration, which is consistent with inhibition of Aurora kinase B activity. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.03.008
• 作为产物：
  描述：

  2-氨基-5-溴吡啶 、 苯甲酰胺 在 potassium phosphate 、 copper(l) iodide 、 乙二醇 作用下， 以 异丙醇 为溶剂， 反应 24.0h， 生成 N-(6-aminopyridin-3-yl)benzamide
  参考文献：
  名称：

  Copper-catalyzed selective C–N bond formation with 2-amino, 2-hydroxy and 2-bromo-5-halopyridine

  摘要：

  铜催化的1,2-二醇促进了在未保护的2-氨基/2-羟基-5-卤代吡啶的富电子C-5位置的氨基化反应，并在2-溴-5-碘代吡啶中选择性地在C-5位置进行氨基化反应，提供了优异的产率。

  DOI：

  10.1039/c7ra08482j

文献信息

• [EN] PROTEIN KINASE INHIBITORS AND USE THEREOF<br/>[FR] INHIBITEURS DE PROTÉINE KINASE ET LEUR UTILISATION
  申请人：MERCK SERONO SA

  公开号：WO2009108670A1

  公开（公告）日：2009-09-03

  Disclosed are benzonaphthyridinyl derivative compounds and analogs thereof, pharmaceutical compositions comprising such compounds and processes for preparing the same. The compounds are useful in the treatment of diseases amenable to kinase signal transduction inhibition, regulation or modulation.

  揭示了苯并萘啶衍生物化合物及其类似物，包括含有这些化合物的药物组合物以及制备这些化合物的方法。这些化合物在治疗对激酶信号传导抑制、调节或调控敏感的疾病中很有用。
• [EN] N- (6-AMINOPYRIDIN-3-YL) -3- (SULFONAMIDO) BENZAMIDE DERIVATIVES AS B-RAF INHIBITORS FOR THE TREATMENT OF CANCER<br/>[FR] DÉRIVÉS DE N-(6-AMINOPYRIDIN-3-YL)-3-(SULFONAMIDO) BENZAMIDE COMME INHIBITEURS DE B-RAF POUR LE TRAITEMENT DU CANCER
  申请人：ARRAY BIOPHARMA INC

  公开号：WO2009111280A1

  公开（公告）日：2009-09-11

  Compounds of Formula (I) are useful for inhibition of Raf kinases. Methods of using compounds of Formula I and stereoisomers and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.

  式(I)的化合物对于抑制Raf激酶是有用的。本文揭示了利用式(I)的化合物及其立体异构体和药学上可接受的盐，在哺乳动物细胞中进行体外、体内和体内诊断、预防或治疗这些疾病，或相关病理条件的方法。
• PROTEIN KINASE INHIBITORS AND USE THEREOF
  申请人：Huck Bayard R.

  公开号：US20110053906A1

  公开（公告）日：2011-03-03

  Disclosed are benzonaphthyridinyl derivative compounds and analogs thereof, pharmaceutical compositions comprising such compounds and processes for preparing the same. The compounds are useful in the treatment of diseases amenable to kinase signal transduction inhibition, regulation or modulation.

  本发明揭示了苯并萘啉衍生物化合物及其类似物，包括含有这些化合物的制药组合物和制备这些化合物的过程。这些化合物可用于治疗易于激酶信号传导抑制、调节或调控的疾病。
• N- (6-AMINOPYRIDIN-3-YL) -3- (SULFONAMIDO) BENZAMIDE DERIVATIVES AS B-RAF INHIBITORS FOR THE TREATMENT OF CANCER
  申请人：Ahrendt Kateri A.

  公开号：US20110003859A1

  公开（公告）日：2011-01-06

  Compounds of Formula (I) are useful for inhibition of Raf kinases. Methods of using compounds of Formula I and stereoisomers and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.

  式(I)的化合物可用于抑制Raf激酶。本文揭示了使用式(I)的化合物及其立体异构体和药物可接受的盐，在哺乳动物细胞中进行体外、体内诊断、预防或治疗相关病理条件的方法。
• US8735584B2
  申请人：——

  公开号：US8735584B2

  公开（公告）日：2014-05-27